Experimental Models of Benign Prostatic Hyperplasia： A Review
10.13422/j.cnki.syfjx.20220293
- VernacularTitle:良性前列腺增生实验模型述评
- Author:
Liang HAN
1
;
Bin WANG
2
;
Xin-rong ZHANG
1
;
Ai-jin PENG
2
;
Yong YANG
2
;
Hai-song LI
2
;
Xiao-xiao ZHANG
3
Author Information
1. Fangshan Hospital ，Beijing University of Chinese Medicine，Beijing 102400，China
2. Dongzhimen Hospital，Beijing University of Chinese Medicine，Beijing 100700，China
3. China Association of Traditional Chinese Medicine，Beijing 100029，China
- Publication Type:Journal Article
- Keywords:
benign prostatic hyperplasia;
model;
modeling method;
review
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2022;28(2):227-235
- CountryChina
- Language:Chinese
-
Abstract:
Benign prostatic hyperplasia （BPH） model， as a carrier of BPH， is vital for exploring the pathogenesis of the disease and evaluating the efficacy of corresponding drugs. This paper reviewed the in vivo and in vitro models of BPH， the modeling principles and methods， and evaluation indicators， and analyzed the advantages and disadvantages of different types of models. At present， the BPH model is getting closer to the clinical characteristics of human BPH， providing powerful support for the evaluation of drug efficacy. Furthermore， the model has been developed towards cytology to allow further research on the pathogenesis of BPH. The relevant testing indicators reflect the core pathological changes of BPH from different levels， providing a guarantee for further exploring the pathogenesis of BPH and the development of prevention and control drugs. However， no model can fully simulate the natural development process of human BPH， and each model and evaluation criterion has its unique advantages and limitations. In terms of model evaluation， most BPH models are assessed based on benign prostate enlargement （BPE）， and there is still a lack of reliable models to simulate BPH progression and combine with bladder dysfunction. In terms of indicator evaluation， symptom-reflected behavioral indicators are absent in the replication of BPH models in animals. The study of the BPH model in traditional Chinese medicine （TCM） only focuses on the replication and investigation of the "disease" model， rather than the "syndromes" and "signs"， which cannot simulate the syndrome differentiation and treatment under the guidance of the TCM theory. In view of the above deficiencies， we should further improve the modeling method based on clinical characteristics， explore the multifactor composite models， especially those of disease-syndrome combination suitable for basic research of TCM， replicate the model closing to disease development， and optimize the evaluation indicators， which is of great theoretical and practical significance to develop drugs for effective prevention and control of BPH.
